Immix Biopharma Changes Certifying Accountant

TL;DR

Immix Biopharma swapped auditors, filing an 8-K on 7/22.

AI Summary

Immix Biopharma, Inc. filed an 8-K on July 22, 2024, reporting a change in its certifying accountant as of July 17, 2024. The company also included financial statements and exhibits in this filing.

Why It Matters

A change in a company's auditor can sometimes signal underlying financial concerns or a desire for a fresh perspective on financial reporting.

Risk Assessment

Risk Level: low — This filing primarily concerns administrative changes related to the company's auditors and financial reporting, with no immediate indication of significant operational or financial distress.

Key Players & Entities

• Immix Biopharma, Inc. (company) — Registrant
• July 17, 2024 (date) — Date of earliest event reported
• July 22, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — registered Common Stock, par value of $0.0001 per share IMMX The Nasdaq Stock Mar

Filing Documents

• form8-k.htm (8-K) — 41KB
• ex16-1.htm (EX-16.1) — 4KB
• 0001493152-24-028595.txt ( ) — 218KB
• immx-20240717.xsd (EX-101.SCH) — 3KB
• immx-20240717_lab.xml (EX-101.LAB) — 33KB
• immx-20240717_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2024 IMMIX BIOPHARMA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-41159 45-4869378 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 11400 West Olympic Blvd. , Suite 200 Los Angeles , CA 90064 (Address of principal executive offices) (310) 651-8041 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) Securities registered pursuant to Section 12(b)of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value of $0.0001 per share IMMX The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 4.01 Changes in Registrant's Certifying Accountant. On May 20, 2024, the partners and professional staff of KMJ Corbin & Company LLP ("KMJ"), which was engaged as the independent registered public accounting firm of Immix Biopharma, Inc. (the " Company "), joined Crowe LLP (" Crowe "), a public accounting, consulting and technology firm. In connection with this transition, on July 17, 2024, the Company, through and with the approval of its Audit Committee, dismissed KMJ as the Company's independent registered accounting firm, and appointed Crowe as its independent registered public accounting firm, effective July 17, 2024. The reports of KMJ on the Company's consolidated financial statements for the two most recently completed fiscal years ended December 31, 2023 and 2022 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles. During the Company's two most recently completed fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through the date of resignation, there were no disagreements between the Company and KMJ on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of KMJ, would have caused KMJ to make reference to the subject matter of the disagreements in connection with its audit reports on the Company's consolidated financial statements. During the Company's two most recently completed fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through the date of resignation, there were no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K). The Company provided KMJ with a copy of this report on Form 8-K in accordance with Item 304(a) of Regulation S-K prior to its filing with the U.S. Securities and Exchange Commission (the " SEC ") and requested that KMJ furnish the Company with a letter addressed to the SEC stating whether it agreed with the above statements and, if it did not agree, the respects in which it did not agree. A copy of the letter from KMJ is filed as Exhibit 16 hereto. During the Company's two most recently completed fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through the date of appointment of Crowe, neither the Company nor anyone on behalf of the Company consulted with Crowe regarding (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements as to which the Company received a written report or oral advice that was an important factor in reaching a decision on any accounting, auditing or financial reporting issue; or (b) any matter that was the subject of a disagreement or a reportable event as defined in Items

View Full Filing

View this 8-K filing on SEC EDGAR